Abstract:OBJECTIVE:It has been reported that high-dose cytarabine (HD-AraC) was very effective for childhood hematological malignancies, especially for improving the long-term survival of high-risk acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and T-cell lymphoid malignancies (T-ALL, T-cell non-Hodgkin's lymphoma). This study aimed to evaluate the pharmacokinetics of HD-AraC for childhood hematological malignancies, and the relationship between the expression of the genes coding the key enzymes for Ara-C metabolism with the outcome of the patients.METHODS:The drug levels of Ara-C in plasma and cerebrospinal fluid were detected with HPLC while HD-AraC was used, the expression of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) mRNA in human leukemia cell lines and the bone marrow cells were investigated in 48 cases of childhood hematological malignancies with RT-PCR methods, and the relationship between the expression of these enzymes mRNA and the outcome of the patients was analyzed.RESULTS:(1) When HD-AraC was used, the plasma levels of Ara-C and Ara-U could be respectively about 50 times and 25 times higher than those obtained when the patients were treated with regular dose of Ara-C treatment, and the level of Ara-C in cerebrospinal fluid could reach about 10% of plasma level of Ara-C. (2) There were significantly different expressions of dCK mRNA in different childhood acute leukemia (AL) patients, which were markedly related to the chemotherapy results. The expression of dCK in ALL was much higher than that in AML and relapsed AL cases. There were no significant differences in expressions of dCK in T-ALL and B lineage ALL. (3) In vitro study found that the expressions of dCK and CDA mRNA did not change in leukemia cell lines incubated at different doses and times of Ara-C.CONCLUSIONS:HD-AraC was a very effective protocol for childhood hematological malignancies for it could significantly elevate the plasma and cerebrospinal fluid drug levels. The expression of dCK may be an important factor in predicting the long-term outcomes of children with hematological malignancies. Good long-term outcomes of the childhood T-ALL could be achieved as the B lineage ALL had been treated with HD-AraC regimen. As the expression levels of dCK were much lower, it may be necessary for the treatment of AML with HD-AraC for consecutive three days.

Cytarabine concentration Monitoring and its correlation to therapeutic response and prognosis in pediatric leukemia treated with high dose cytarabine

Study on clinical responses and pharmokinetics of cytarabine following its high dose administration

Determination of Cytarabine at High-Dose and Investigation of Curative Effect in Children with Acute Leukemia

Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: a Multicenter Study of 112 Chinese Patients.

[Relationship Between the Expression of the Genes Encoding the Key Enzymes for Cytarabine Metabolism and the Pharmacokinetics of Cytarabine in the Treatment of Childhood Acute Leukemia with High-Dose Cytarabine].

Determination of Ara-C in plasma and Ara-CTP in leukemic cells after intravenous infusion of high-dose Ara-C in patients with acute leukemia and analysis of influence factors

[Efficacy and Safety Analysis of Different Dose Idarubicin Plus Cytarabine Regimen As Induction Chemotherapy for Young Patients with De-Novo Acute Myeloid Leukemia].

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Determination of plasma and cerebrospinal fluid drug concentrations during high-dose cytosine arabinoside treatment

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease

Comparison Of Clinical Efficacy Of Cytarabine With Different Regimens In Postremission Consolidation Therapy For Adult T(8;21) Aml Patients: A Multicenter Retrospective Study In China

Curative Effect Analysis of High Dose Cytosine Arabinoside in the Chemotherapy for Childhood Acute Lymphoblastic Leukemia

Long-term Effect and Plasma Drug Concentration of Childhood Malignant Hematolopathies Treated with High-Dose AraC

HPLC determination of intra-cellular Ara-CTP

Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis

An analysis of 248 cycles of moderate dose cytarabine for acute myeloid leukemia—outcome and side effects

Effects of High-dose Cytarabine Treating 15 Cases Involving Remission of Acute Myeloid Leukemia

Relationship Between Activities of Key Enzymes of Ara-C Metabolism and Clinical Efficacy in Children with Hematopoietic Malignancies

Expression of Deoxycytidine Kinase and Cytidine Deaminase Mrna in Children with Acute Leukemia

Long-term therapeutic effect of high-dose Ara-C based protocols on childhood acute myeloblastic leukemia

The expression of cell membrane transporter-human equilibrative nucleoside transporter 1 in leukemia cell lines treated with Ara-C